Redeye: Imint - China is Making its Mark

Redeye lower our estimates and valuation for Imint significantly as a consequence of a slowdown in China, which we believe represents almost 80% of revenues. The trade war, Chinese companies making efforts to reduce their dependence on foreign suppliers (including Huawei, Imint’s partner) and the Coronavirus, are clearly a challenging environment.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye – Research Powered Investment Banking.


We’re all about video enhancement

Book a Demo